Results 11 to 20 of about 6,454 (219)

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature. [PDF]

Clin Case Rep
ABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Malik M, Amjad H, Malik K, Saleem MS, Akhtar S, Paracha M, Abid M, Shafi N, Raza AA, Samadi A, Jaffri SA.   +10 more
europepmc   +2 more sources

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

Biomedicines, 2023
The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for identifying optimal therapies for the management of these conditions ...
Alexandros Leonidas Liarakos, Chrysi Koliaki   +1 more
doaj   +1 more source

Tirzepatide for type 2 diabetes

Drugs in Context, 2023
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats

Frontiers in Pharmacology, 2023
Background: One of the typical symptoms of diabetes mellitus patients was memory impairment, which was followed by gradual cognitive deterioration and for which there is no efficient treatment.
Xiying Guo, Min Lei, Jiangyan Zhao, Min Wu, Zhanhong Ren, Xiaosong Yang, Changhan Ouyang, Xiufen Liu, Chao Liu, Qingjie Chen   +9 more
doaj   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop   +17 more
doaj   +1 more source

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue

Molecular Metabolism, 2022
Objectives: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D).
Ricardo J. Samms, GuoFang Zhang, Wentao He, Olga Ilkayeva, Brian A. Droz, Steven M. Bauer, Cynthia Stutsman, Valentina Pirro, Kyla A. Collins, Ellen C. Furber, Tamer Coskun, Kyle W. Sloop, Joseph T. Brozinick, Christopher B. Newgard   +13 more
doaj   +1 more source

Tirzepatide and prevention of chronic kidney disease [PDF]

, 2023
Chronic kidney disease; Diabetes mellitus; ObesityMalaltia renal crònica; Diabetis mellitus; ObesitatEnfermedad renal crónica; Diabetes mellitus; ObesidadTirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes ...
Bosch, Catalina, Carriazo Julio, Sol Maria, Fernandez-Fernandez, Beatriz, Ortiz Arduan, Alberto, Soler, María José   +4 more
core   +1 more source

Tirzepatide (Mounjaro)-induced acute pancreatitis and ketoacidosis in an adult nondiabetic patient

Saudi Journal for Health Sciences
Tirzepatide (Mounjaro) is a new medication approved for type 2 diabetes and obesity treatment. It works by activating the receptors for both glucose-dependent insulinotropic peptide and glucagon-like peptide-1.
Asma Ali Sallam, Bdoor Attaulla Alenezi, Muneerah M. Albugami   +2 more
doaj   +1 more source

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Frontiers in Endocrinology, 2023
PurposeA systematic review and meta-analysis was conducted to synthesize the available data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes (T2D) and obesity.MethodsA ...
Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li   +5 more
doaj   +1 more source

Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes [PDF]

Obesity is a main trigger for development of type 2 diabetes. Tirzepatide is a dual receptor agonist of glucagon-like 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and is a potent agent for controlling glycemic control and reducing ...
Nasser Mikhail
core   +2 more sources